Nestlé Health Science has announced that it will make an investment of US$145 million, representing a 15% stake, in the California-based company Aimmune Therapeutics. The investment is said to be part of Nestlé Health Science’s commitment to innovation in the management of food allergies and building a broad portfolio of solutions for patients.
Aimmune is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Their products aim to desensitise and protect patients from the consequences of accidental exposure to life-threatening allergens. Aimmune’s lead product AR101 is in Phase III trial for peanut allergy, having a US FDA Breakthrough Therapy Designation. The current trial is expected to deliver results in the fourth quarter of 2017, and it is hoped these may support the filing of marketing authorization in the US and Europe.
In addition to the financial investment by Nestlé Health Science, the companies have entered into a two-year collaboration aimed at speeding up the development of innovative oral therapies designed to desensitize people with food allergies.
Earlier this year Nestlé Health Science partnered with DBV Technologies on the development of a skin-patch test tool for the improved diagnosis of cow’s milk protein allergy.
Read the full press release on Nestlé Health Science’s website.